Promethera Biosciences To Present Data From Trial In Liver Failure.

DURHAM, N.C., March 27, 2019 -- Interim safety data together with early signals of efficacy will be discussed in an oral presentation at a medical meeting April 10-14 in Vienna, Austria.

HepaStem comproses liver stem cells obtained from ethically donated healthy human organs and expanded in GMP culture conditions.

The product candidate is being evaluated in a Phase 2a clinical trial in acute on chronic liver failure (ACLF) and acute decompensation (AD).

Promethera is pioneering the use of liver-derived stem cells for the treatment of ACLF and nonalcoholic fatty liver disease (NASH).

The preliminary safety results are encouraging as the company advances HepaStem in the clinic.

In the study, single and repeated infusions of HepaStem were shown safe in this patient population.

In addition, the Model for End Stage Liver Disease score (MELD), Child-Pugh score and bilirubin levels, three indicators of liver disease severity, had decreased along the trial in treated patients, which is regarded as an encouraging sign of efficacy.

The data will be presented at the International Liver Congress acute-on-chronic liver failure (ACLF) or acute decompensation (AD) at risk of developing ACLF by principal investigator Frederic Nevens of KU Leuven (Belgium) during the plenary general session of the International Liver Congress 2019.

Contact: http://www.promethera.com